Cardiac Insight, Inc. Partners with VivoSense® (Vivonoetics, Inc.) to Expand the Use of Its Wearable Cardiac Sensors in Regulated Pharmaceutical Clinical Trials and Other Healthcare Research Applications
Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac biosensors and clinical diagnostic software systems featuring proprietary automated data analysis algorithms, announced today it has partnered with VivoSense®, a leader in integration and specialized analysis of wearable sensor data for research and clinical trials. Together, both companies will deliver enhanced research analytics to help VivoSense expand the use of wearable biosensors for pharmaceutical clinical trials and other healthcare applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181101005394/en/
“Sophisticated new analytics are the key to making sense of the complex data sets generated by human study participants in response to new drug candidates and genetics-driven population health research. Using the class-leading Cardiac Insight Cardea SOLO™ ECG Sensor data with VivoSense software, data cleaning, robust analytics and regulatory-compliant biomarkers, we expect to enable new discoveries,” said Dudley Tabakin, Chief Executive Officer and Co-Founder of VivoSense. “The unique attributes and access to data enabled by Cardea SOLO strongly support our mission to advance clinical trials through the increasing use of wearable technology.”
VivoSense ingests data from many different wearable sensors, from high-resolution cardiorespiratory and other cardiac sensors like Cardea SOLO to wrist-worn activity trackers. This data from on-body sensors is integrated, cleaned and synchronously analyzed with robust algorithms and scientific oversight from the VivoSense platform. The VivoSense solution opens all clinical trials to the accurate use of wearable technology, providing a new level of data.
“Our partnership with VivoSense is forging new frontiers and capabilities in healthcare research. Our complex raw ECG data and automated analytics, easily obtained by our wearable ECG, Cardea SOLO, combined with the VivoSense platform integration will provide a new level of understanding into the effectiveness of emerging medical and pharmaceutical innovations, as well as to potentially develop completely new biomarkers,” said Brad Harlow, Chief Executive Officer of Cardiac Insight, Inc. “Contributing to the advancement of health research is an important component of our mission. We look forward to providing researchers a more comprehensive level of data analytics to improve disease prevention, detection and treatment.”
Comfortable and unobtrusive wearable cardiorespiratory sensors are finding ubiquitous use in sports and fitness research, longitudinal healthcare monitoring, and in regulated clinical trials. The very large physiological data sets generated by these sensors are the key to monitoring health and providing a greater understanding of the effects of new medicines and therapies.
About VivoSense (Vivonoetics, Inc.)
VivoSense (vivosense.com), Tel: +1 (858) 876-8486, founded in 2009, and based in Newport Beach, CA, is a leader in wearable sensor data analytics for clinical research. Through the use of VivoSense core laboratory services and VivoSense® technology, pharmaceutical researchers can now obtain high-quality data solutions to continually and passively describe a patient's longitudinal pulmonary status in clinical, ambulatory and home settings. VivoSense has supported research and clinical trials using VivoSense® at over 500 leading pharmaceutical, research and academic institutions across a wide range of disease states, including sleep disordered breathing, congestive heart failure, chronic obstructive pulmonary disease, Spinal Muscular Atrophy, Rett Syndrome and cystic fibrosis. For more information, visit www.vivosense.com.
About Cardiac Insight, Inc.
Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. developer of advanced body-worn digital health care information systems through its proprietary software, algorithms and devices. The company is revolutionizing sensor technology to advance cardiac care, beginning with its two flagship products – the wearable ECG Sensor and Analysis Software System, Cardea SOLO™ (www.cardeasolo.com) and Cardea 20/20 ECG™, the only 12-lead test that incorporates the International Criteria for identification of the risk of Sudden Cardiac Arrest in young athletes. Founded in 2008, Cardiac Insight is an ISO-certified company and is based in Kirkland, Washington, USA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005394/en/